Moderna (NASDAQ:MRNA) Shares Up 1.2% – Here’s Why

Moderna, Inc. (NASDAQ:MRNA) shares traded up 1.2% during trading on Tuesday. The stock traded as high as $218.48 and last traded at $216.25. Approximately 13,355,521 shares changed hands during trading, an increase of 9% from the average daily volume of 12,250,907 shares. The stock had previously closed at $213.74.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Reports of encouraging results for Moderna’s personalized mRNA cancer vaccine have fueled optimism that oncology could become a major long-term growth driver. A planned NIH-backed initiative to accelerate personalized cancer-vaccine development is providing an additional industry catalyst. Moderna Cancer Vaccine Breakthrough
• Positive Sentiment: Moderna’s Nasdaq-100 inclusion has likely generated index-related buying and increased visibility among institutional investors, helping extend the recent rally. MRNA Stock Gains Over $4 Billion
• Positive Sentiment: Health Canada is reviewing Moderna’s next-generation mRNA flu vaccine, which could reduce hospitalizations if approved and give the company another potential growth opportunity beyond COVID-19 and cancer treatments. Health Canada Flu Vaccine Review
• Neutral Sentiment: Moderna will report third-quarter 2026 results on November 6, giving investors a forthcoming catalyst for evaluating revenue trends, cash usage, and progress on its pipeline. Moderna Third-Quarter 2026 Results
• Negative Sentiment: The rapid rally has prompted profit-taking and renewed concern that much of the cancer-vaccine and Nasdaq-100 news is already reflected in the stock’s valuation. Older analyst price targets cited by Quiver Quantitative are substantially below the current market level, underscoring downside risk if expectations weaken.
• Negative Sentiment: Reported open-market activity shows Moderna insiders made no purchases and sold shares during the past six months. That selling may reinforce investor caution after the stock’s sharp advance.

Analysts Set New Price Targets

Several equities research analysts have commented on MRNA shares. Singular Research raised shares of Moderna to a “hold” rating in a research report on Wednesday, September 23rd. Piper Sandler increased their price objective on shares of Moderna from $77.00 to $167.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Barclays raised their price objective on Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a report on Monday, August 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Finally, The Goldman Sachs Group lifted their target price on Moderna from $67.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday, August 19th. Seven analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $100.60.

Moderna Stock Performance

The firm has a market capitalization of $86.34 billion, a price-to-earnings ratio of -27.07 and a beta of 1.09. The stock’s fifty day moving average is $143.25 and its two-hundred day moving average is $86.30. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter last year, the company posted ($2.13) earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current year.

Insider Activity

In related news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 118,882 shares of company stock valued at $16,862,280. 10.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MRNA. Merck & Co. Inc. acquired a new stake in shares of Moderna in the second quarter valued at approximately $161,642,545. Louisiana State Employees Retirement System acquired a new stake in Moderna during the first quarter worth approximately $899,000. Bank of New York Mellon Corp acquired a new stake in Moderna during the second quarter worth approximately $119,168,000. Contravisory Investment Management Inc. increased its stake in Moderna by 1,387.6% during the 2nd quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock worth $1,696,000 after acquiring an additional 22,590 shares during the period. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Moderna during the 2nd quarter worth $1,013,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.